Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review

Breast

Volumn 24, Issue 2, 2015, Pages 100-106

  Bernier, Jacques ^a   Poortmans, Philip ^b  

^a Genolier Swiss Medical Network SA   (Switzerland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA mutation; Breast cancer; Breast conserving therapy; Outcome; Radiation therapy; Radiosensitivity

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CONTRALATERAL BREAST CANCER; DNA DAMAGE; GENE MUTATION; GERMLINE MUTATION; HUMAN; MASTECTOMY; NONHUMAN; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE RADIATION THERAPY; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; RADIOSENSITIVITY; REVIEW; SECOND CANCER; SURVIVAL RATE; TUMOR CELL; TUMOR SUPPRESSOR GENE; BREAST; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METABOLISM; PHYSIOLOGY; RADIATION DOSE; TUMOR RECURRENCE;

BREAST; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, RADIATION-INDUCED; RADIATION TOLERANCE;

EID: 84925258766     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.12.003     Document Type: Review

References (61)

1. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
2. Miki Y., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., et al. Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
3. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
4. Feuer E.J., Wun L.M., Boring C.C., Flanders W.D., Timmel M.J., Tong T. The lifetime risk of developing breast cancer. JNatl Cancer Inst 1993, 85:892-897.
5. Antoniou A., Pharoah D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
6. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. JClin Oncol 2007, 25:1329-1333.
7. Begg C.B.1, Haile R.W., Borg A., Malone K.E., Concannon P., Thomas D.C., et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299:194-201.
8. Pierce L.J., Haffty B.G. Radiotherapy in the hereditary breast cancer. Semin Radiat Oncol 2011, 21:43-50.
9. Narod S.A., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000, 356:1876-1881. Hereditary Breast Cancer Clinical Study Group.
10. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. JClin Oncol 2004, 22:1055-1062.
11. Sharan S.K., Morimatsu M., Albrecht U., Lim D.S., Regel E., Dinh C., et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997, 386:804-810.
12. Steel G.G. From targets to genes: a brief history of radiosensitivity. Phys Med Biol 1996, 41:205-222.
13. Claus E.B., Schildkrant J.M., Thompson W.D., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77:2318-2324.
14. Rothkamm K., Krüger I., Thompson L.H., Löbrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003, 23:5706-5715.
15. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., et al. Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
16. Saleh-Gohari N., Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 2004, 32:3683-3688.
17. Powell S.N., Kachnic L.A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22:5784-5791.
18. Lok B.H., Powell S.N. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res 2012, 18:6400-6406.
19. Xu B., Kim S., Kastan M.B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001, 21:3445-3450.
20. Moynahan M.E., Pierce A.J., Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001, 7:263-272.
21. Snouwaert J.N., Gowen L.C., Latour A.M., Mohn A.R., Xiao A., DiBiase L., et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999, 8:7900-7907.
22. Chen C.F., Chen P.L., Zhong Q., Sharp Z.D., Lee W.H. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. JBiol Chem 1999, 12:32931-32935.
23. Febrer E., Mestres M., Caballín M.R., Barrios L., Ribas M., Gutiérrez-Enríquez S., et al. Mitotic delay in lymphocytes from BRCA1 heterozygotes unable to reduce the radiation-induced chromosomal damage. DNA Repair 2008, 7:1907-1911.
24. Le Page F., Randrianarison V., Marot D., Cabannes J., Perricaudet M., Feunteun J., et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000, 60:5548-5552.
25. Saha T., Rih J.K., Roy R., Ballal R., Rosen E.M. Transcriptional regulation of the base excision repair pathway by BRCA1. JBiol Chem 2010, 285:19092-19105.
26. Harkin D.P., Bean J.M., Miklos D., Song Y.H., Truong V.B., Englert C., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999, 97:575-586.
27. Fabbro M., Henderson B.R. BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters. Cancer Lett 2008, 263:189-196.
28. Wang H., Zeng Z., Bui T., DiBiase S.J., Qin W., Xia F., et al. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumour cells deficient in BRCA1 or BRCA2. Cancer Res 2001, 61:270-277.
29. DiBiase S.J., Zeng Z.C., Chen R., Hyslop T., Curran W.J., Iliakis G. DNA-dependent protein kinase stimulates an independently active, non-homologous, end-joining apparatus. Cancer Res 2000, 60:1245-1253.
30. Ernestos B., Nikolaos P., Koulis G., Eleni R., Konstantinos B., Alexandra G., et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. Int J Radiat Oncol Biol Phys 2010, 76:1199-1205.
31. Buchholz T.A., Wu X., Hussain A., Tucker S.L., Mills G.B., Haffty B., et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 and BRCA2. Int J Cancer 2002, 97:557-561.
32. Kote-Jarai Z., Salmon A., Mengitsu T., Copeland M., Ardern-Jones A., Locke I., et al. Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers. Br J Cancer 2006, 94:308-310.
33. Barwell J., Pangon L., Georgiou A., Kesterton I., Langman C., Arden-Jones A., et al. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer 2007, 121:1631-1636.
34. Nieuwenhuis B., Van Assen-Bolt A.J., Van Waarde-Verhagen M.A., Sijmons R.H., Van der Hout A.H., Bauch T., et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002, 78:285-295.
35. Baeyens A., Thierens H., Claes K., Poppe B., de Ridder L., Vral A. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Biol 2004, 80:745-756.
36. Honrado E., Benítez J., Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol 2006, 59:27-39.
37. Pierce L.J., Strawderman M., Narod S.A., Oliviotto I., Eisen A., Dawson L., et al. Effectof radiotherapy following breast-conserving treatment in women withbreast cancer and germline BRCA1/2 mutations. JClin Oncol 2000, 18:3360-3369.
38. Shanley S., McReynolds K., Ardern-Jones A., Ahern R., Fernando I., Yarnold J., et al. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006, 12:7033-7038.
39. Park H., Choi D.H., Noh J.M., Huh S.J., Park W., Nam S.J., et al. Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol 2014, 90:90-94.
40. Haffty B.G., Harrold E., Khan A.J., Pathare P., Smith T.E., Turner B.C., et al. Conservatively managed early onset breast cancer: outcome as a function of germline BRCA1/2 status. Lancet 2002, 359:1471-1477.
41. Pierce L.J., Levin A.M., Rebbeck T.R., Ben-David M.A., Friedman E., Solin L.J., et al. Ten year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage. I/II breast cancer. JClin Oncol 2006, 24:2437-2443.
42. Garcia-Etienne C.A., Barile M., Gentilini O.D., Botteri E., Rotmensz N., Sagona A., et al. Breast conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?. Ann Surg Oncol 2009, 16:3380-3387.
43. Kirova Y.M., Savignoni A., Sigal-Zafrani B., de La Rochefordiere A., Salmon R.J., This P., et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 2010, 120:119-126.
44. Robson M., Levin D., Federici M., Satagopan J., Bogolminy F., Heerdt A., et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. JNatl Cancer Inst 1999, 91:2112-2117.
45. Pierce L.J., Phillips K.-A., Griffith K.A., Buys S., Gaffney D.K., Moran M.S., et al. Local therapy in BRCA1/2 carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
46. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Olivotto I., Warner E., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. JClin Oncol 2004, 22:2328-2335.
47. Hooning M.J., Aleman B.M., Hauptmann M., Baaijens M.H., Klijn J.G., Noyon R., et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. JClin Oncol 2008, 26:5561-5568.
48. Bernstein J.L., Thomas D.C., Shore R.E., Robson M., Boice J.D., Stovall M., et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE Study Report. Eur J Cancer 2013, 49:2979-2985. WECARE Study Collaborative Group.
49. Croshaw R.L., Marshall M.L., Williams T.L., Erb K.M., Julian T.B. Prophylactic and therapeutic breast conservation in BRCA1/2 mutation carriers. Int J Breast Cancer 2011, 2011:481563.
50. Robson M.E., Chappuis P.O., Satagopan J., Wong N., Boyd J., Goffin J.R., et al. Acombined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6:R8-R17.
51. Brekelmans C.T.M., Tilanus-Linthorst M.M.A., Seynaeve C., vd Ouweland A., Menke-Pluymers M.B., Bartels C.C., et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007, 43:867-876.
52. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAm Med Assoc 2010, 304:967-975.
53. Robson M., Svahn T., McCormick B., Borgen P., Hudis C.A., Norton L., et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005, 103:44-51.
54. El-Tamer M., Russo D., Troxel A., Bernardino L.P., Mazziotta R., Estabrook A., et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 2004, 11:157-164.
55. Rennert G., Bisland-Naggan S., Barnett-Griness O., Bar-Joseph N., Zhang S., Rennert H.S., et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. NEngl J Med 2007, 357:115-123.
56. Turner B.C., Harrold E., Matloff E., Smith T., Gumbs A.A., Beinfield M., et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast conserving management in patients with BRCA1/BRCA2 mutations. JClin Oncol 1999, 17:3017-3024.
57. Gaffney D.K., Brohet R.M., Lewis C.M., Holden J.A., Buys S.S., Neuhausen S.L., et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998, 47:129-136.
58. Fourquet A., Stoppa-Lyonnet D., Kirova Y.M., Sigal-Zafrani B., Asselain B. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 2009, 32:127-131. Institut Curie Breast Cancer Study Group, Institut Curie Breast Ovary Cancer Risk Study GroupInstitut Curie Breast Ovary Cancer Risk Study Group.
59. Nilsson M.P.1, Hartman L., Kristoffersson U., Johannsson O.T., Borg A., Henriksson K., et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2014, 147:571-578.
60. Seynaeve C., Verhoog L.C., van de Bosch L.M., van Geel A.N., Menke-Pluymers M., Meijers-Heijboer E.J., et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 2004, 40:1150-1158.
61. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., Sigal-Zafrani B., Fabre N., Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005, 41:2304-2311. Institut Curie Breast Cancer Study Group.